


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

1. (currently amended) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is acyl, substituted acyl, oxycarbonyl and substituted oxycarbonyl;

R<sup>2</sup> is alkyl, -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup> or -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>-S(O)<sub>o</sub>R<sup>5</sup>;

m is 1 or 2;

n and o are independently 0, 1 or 2;

R<sup>3</sup> is -CH<sub>2</sub>CONH<sub>2</sub>;

R<sup>4</sup> is NH<sub>2</sub>;

R<sup>5</sup> is ~~alkyl~~ ethyl, propyl, butyl, alkenyl, alkynyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, oxycarbonyl or substituted oxycarbonyl;

~~with the proviso that:~~

~~R<sup>5</sup> is not methyl when m is 1.~~

- 2-4. (canceled)

5. (previously presented) The compound of Claim 1, wherein R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup> or -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>-S(O)<sub>o</sub>R<sup>5</sup>.

- 6-18. (canceled)

19. (original) The compound of Claim 1, wherein A is a D amino acid.

20. (original) The compound of Claim 1, wherein A, B and C are L amino acids and the  $\alpha$  carbons adjacent to  $R^2$  and  $R^3$ , respectively have the L configuration.

21. (canceled)

22. (previously presented) The compound of Claim 1, wherein  $R^1$  is acyl.

23. (original) The compound of Claim 22, wherein  $R^1$  is  $-C(O)CH_3$  and  $R^2$  is alkyl.

24. (original) The compound of Claim 23, wherein  $R^2$  is methyl or allyl.


25. (original) The compound of Claim 22, wherein  $R^1$  is  $-C(O)CH_3$ ,  $R^2$  is  $-(CH_2)_mS(O)_nR^5$  and m is 1.

26. (Currently amended) The compound of Claim 25, wherein n is 0 and  $R^5$  is ~~alkyl~~ ethyl, propyl, butyl, alkenyl, alkynyl or substituted alkyl.

27. (withdrawn) The compound of Claim 26, wherein  $R^5$  is ethyl, *t*-butyl or  $-CH_2NHC(O)CH_3$ .


28. (withdrawn) The compound of Claim 25, wherein n is 0 and  $R^5$  is arylalkyl or substituted arylalkyl.

29. (withdrawn) The compound of Claim 28, wherein  $R^5$  is




30. (original) The compound of Claim 25, wherein n is 0 and  $R^5$  is acyl or substituted acyl.

31. (original) The compound of Claim 30, wherein  $R^5$  is



32. (withdrawn) The compound of Claim 25, wherein n is 0 and  $R^5$  is oxycarbonyl or substituted oxycarbonyl.

33. (withdrawn) The compound of Claim 32, wherein R<sup>5</sup> is



34. (original) The compound of Claim 22, wherein R<sup>1</sup> is -C(O)CH<sub>3</sub>, R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>-S(O)<sub>o</sub>R<sup>5</sup> and m is 1.

35. (Currently amended) The compound of Claim 34, wherein n and o are 0 and R<sup>5</sup> is ~~alkyl~~ ethyl, propyl, butyl, alkenyl, alkynyl or aryl.

36. (Currently amended) The compound of Claim 35, wherein R<sup>5</sup> is ~~methyl~~, ethyl or phenyl.

37. (original) The compound of Claim 22, wherein R<sup>1</sup> is -C(O)CH<sub>3</sub>, R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup> and m is 2.

38. (Currently amended) The compound of Claim 37, wherein n is 0 and R<sup>5</sup> is ~~alkyl~~ ethyl, propyl, butyl, alkenyl, alkynyl or arylalkyl.


39. (original) The compound of Claim 38, wherein R<sup>5</sup> is ~~methyl or~~ benzyl.

40. (~~withdrawn, currently amended~~) The compound of Claim 37, wherein n is 1 or 2 and R<sup>5</sup> is ~~alkyl~~ ethyl, propyl, butyl, alkenyl, or alkynyl.

41. (canceled)

42. (withdrawn) The compound of Claim 37, wherein n is 0 and R<sup>5</sup> is acyl.

43. (withdrawn) The compound of Claim 42, wherein R<sup>5</sup> is pivaloyl or



44-54. (canceled)

55. (currently amended) The compound of Claim 1, wherein R<sup>1</sup> is acyl, R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup>, m is 1 and R<sup>5</sup> is ~~alkyl~~ ethyl, propyl, butyl, alkenyl, or alkynyl.


56-57. (canceled)

58. (previously presented) The compound of Claim 22, wherein R<sup>1</sup> is -C(O)CH<sub>3</sub>.

59. (Currently amended) A pharmaceutical composition comprising a compound of any of claims 1, 5, 19, 20, ~~22-43, 55, 56~~ 22-40, 42-43 and 58 and a pharmaceutically acceptable diluent, excipient or adjuvant.

60-65. (canceled)

66. (new) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is acyl, substituted acyl, oxycarbonyl and substituted oxycarbonyl;

R<sup>2</sup> is  $-(CH_2)_mS(O)_nR^5$ ;

m is 1 or 2;


n is 1 or 2;

R<sup>3</sup> is  $-CH_2CONH_2$ ;

R<sup>4</sup> is  $NH_2$ ;

R<sup>5</sup> is methyl.

67. (new) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is acyl, substituted acyl, oxycarbonyl and substituted oxycarbonyl;

R<sup>2</sup> is  $-(CH_2)_mS(O)_n-S(O)_oR^5$ ;

m is 1;


n and o are 0;

R<sup>3</sup> is  $-CH_2CONH_2$ ;

$R^4$  is  $\text{NH}_2$ ;

$R^5$  is methyl.

68. (new) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

$R^1$  is  $\text{C}(\text{O})\text{CH}_3$ ;

$R^2$  is  $-(\text{CH}_2)_m\text{S}(\text{O})_n\text{R}^5$ ;

m is 1;


n is 0;

$R^3$  is  $-\text{CH}_2\text{CONH}_2$ ;

$R^4$  is  $\text{NH}_2$ ;

$R^5$  is methyl.

69. (new) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

$R^1$  is  $\text{C}(\text{O})\text{CH}_3$ ;

$R^2$  is  $-(\text{CH}_2)_m\text{S}(\text{O})_n\text{R}^5$ ;

m is 1;


n is 0;

$R^3$  is  $-\text{CH}_2\text{CONH}_2$ ;

R<sup>4</sup> is NH<sub>2</sub>;

R<sup>5</sup> is acetyl.

70. (new) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is acetyl;

R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup>;


m is 1;

n is 0;


R<sup>3</sup> is -CH<sub>2</sub>CONH<sub>2</sub>;

R<sup>4</sup> is NH<sub>2</sub>;

R<sup>5</sup> is



71. (new) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is C(O)CH<sub>3</sub>;

$R^2$  is  $-\text{CH}_2\text{S-pivaloyl}$ ,  $-(\text{CH}_2)_2\text{S-pivaloyl}$ ,  $-(\text{CH}_2)_2\text{S-benzoyl}$ ,  $-\text{CH}_2\text{S-S-methyl}$ ,  
or  $-\text{CH}_2\text{S-S-phenyl}$ ;

$R^3$  is  $-\text{CH}_2\text{CONH}_2$ ;

$R^4$  is  $\text{NH}_2$ .